ScreenerHero

CAPR Capricor Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · capricor.com
8.100USD+4.52%Mkt Cap: 470.93M $P/E: —

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap470.93M USD
Enterprise Value303.69M USD
Revenue (TTM)—
Gross Profit-99.73M USD
Net Income (TTM)-105.04M USD
Revenue/Share—
Last Price8.100 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees231
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.24
PEG0.38
EV/EBITDA-2.28
EV/Revenue—
P/S—
P/B1.83
EPS (TTM)-2.44
EPS (Forward)-1.48
52W Range
2.96014% of range40.37
52W High40.37 USD
52W Low2.960 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-34.35%
ROA-29.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-69.81M USD
CapEx (TTM)11.72M USD
FCF Margin—
FCF Yield-18.94%
Net Debt-146.89M USD
Net Debt/EBITDA1.10
Balance Sheet
Debt/Equity0.05
Current Ratio7.35
Quick Ratio7.22
Book Value/Sh4.24 USD
Cash/Share4.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 5, 2019
Splits
Last Split1:10
Split DateJun 5, 2019
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.00 USD
Upside (mean)+233.3%
Target Range7.000 USD – 54.00 USD
7.000+233.3% to mean54.00
# Analysts5
Ownership
Shares Out.58.14M
Float42.60M
Insiders9.44%
Institutions76.30%
Short Interest
Short Ratio2.6d
Short % Float37.37%
Short % Out.33.85%
Shares Short19.68M
Short (prev mo.)17.75M
Technical
SMA 507.512 (+7.8%)
SMA 20022.51 (-64.0%)
Beta0.61
S&P 52W Chg16.45%
Avg Vol (30d)5.52M
Avg Vol (10d)4.92M
Technical Indicators
RSI (14)43.9
MACD-0.3468
MACD Signal-0.3692
MACD Hist.+0.0225
BB Upper9.555 USD
BB Middle8.646 USD
BB Lower7.736 USD
BB Width21.03%
ATR (14)0.9194 USD
Vol Ratio (20d)0.76x